1. Home
  2. NXE vs RGEN Comparison

NXE vs RGEN Comparison

Compare NXE & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexgen Energy Ltd.

NXE

Nexgen Energy Ltd.

N/A

Current Price

$10.35

Market Cap

7.5B

Sector

N/A

ML Signal

N/A

Logo Repligen Corporation

RGEN

Repligen Corporation

N/A

Current Price

$176.26

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NXE
RGEN
Founded
2011
1981
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
6.6B
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
NXE
RGEN
Price
$10.35
$176.26
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$167.67
AVG Volume (30 Days)
4.5M
971.2K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
286.96
EPS
N/A
0.24
Revenue
N/A
$141,236,000.00
Revenue This Year
N/A
$14.30
Revenue Next Year
$75.07
$14.52
P/E Ratio
N/A
$758.46
Revenue Growth
N/A
35.10
52 Week Low
$7.33
$100.99
52 Week High
$13.96
$188.73

Technical Indicators

Market Signals
Indicator
NXE
RGEN
Relative Strength Index (RSI) 54.13 66.61
Support Level $10.45 $156.65
Resistance Level $10.91 $188.73
Average True Range (ATR) 0.46 6.21
MACD 0.04 0.29
Stochastic Oscillator 45.39 62.11

Price Performance

Historical Comparison
NXE
RGEN

About NXE Nexgen Energy Ltd.

NexGen Energy Ltd is an exploration and development stage entity engaged in the acquisition, exploration, evaluation, and development of uranium properties in Canada. The Rook I Project is a development-stage uranium project in Canada. The Company also holds a prospective portfolio of uranium exploration projects in the historic eastern Athabasca Basin.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: